Gazi Medical Journal (Apr 2024)
Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment
Abstract
Objective: There are many anti-cholinergic drugs that are used to treat overactive bladder. Mirabegron was created to lessen the many side effects of these drugs, especially acute urinary retention. The use of mirabegron along with anti-cholinergic is a safe and effective treatment method. In addition, anti-cholinergic therapies have been developed that reduce bladder overactivity with side effects similar to those of lower dose approaches and with higher efficacy. Methods: In this study, data were collected for 35 male patients (group 1) in whom propiverine 45 mg was administered instead of propiverine 30 mg treatment; the other 31 patients (group 2) were given mirabegron 50 mg on propiverine 30 mg treatment. Patients were called for control at 1 and 6 months; adherence and persistence were determined; residual urine volumes were measured by ultrasonography; and complaints were evaluated using the Overactive Bladder Assessment Form (OAB-V8). Results: When the ages and chronic diseases of the patients in groups 1 and 2 were compared, there was no significant difference between the groups. Similar rates of adherence and persistence were observed between the groups. There were no statistically significant differences between the groups in terms of daily micturition and weekly incontinence frequencies, post-voiding residual urine volumes, side effects (especially dry mouth), and responses and scores on the OAB-V8 forms. Conclusion: Propiverine 45 mg monotherapy or propiverine 30 mg and mirabegron combined treatment can be safely administered with similar efficacy and limitations.
Keywords
